WO2011098578A3 - Liposome system for ocular administration - Google Patents

Liposome system for ocular administration Download PDF

Info

Publication number
WO2011098578A3
WO2011098578A3 PCT/EP2011/052061 EP2011052061W WO2011098578A3 WO 2011098578 A3 WO2011098578 A3 WO 2011098578A3 EP 2011052061 W EP2011052061 W EP 2011052061W WO 2011098578 A3 WO2011098578 A3 WO 2011098578A3
Authority
WO
WIPO (PCT)
Prior art keywords
liposomes
pharmaceutical formulation
eye
active ingredient
ocular administration
Prior art date
Application number
PCT/EP2011/052061
Other languages
French (fr)
Other versions
WO2011098578A2 (en
Inventor
Daniel Bar-Shalom
Simon SKJØDE JENSEN
Original Assignee
Bioneer A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioneer A/S filed Critical Bioneer A/S
Publication of WO2011098578A2 publication Critical patent/WO2011098578A2/en
Publication of WO2011098578A3 publication Critical patent/WO2011098578A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention concerns a pharmaceutical formulation for ocular or intra-ocular administration providing sustained or delayed release of at least one active ingredient, said pharmaceutical formulation comprising liposomes, said liposomes comprising at least part of said at least one active ingredient, at least part of said liposomes exhibiting a charge increasing the adherence of the charged liposomes to the eye after administration, in particular when said pharmaceutical formulation is for ocular administration, and wherein at least one of the lipids in the liposomes is degradable by sPLA2 activity, allowing sustained or delayed release of said at least one active ingredient from said liposomes upon contact with tear fluid or with sPLA2 in the eye or in the vicinity of the eye. The pharmaceutical formulation is useful for ophthalmic indications.
PCT/EP2011/052061 2010-02-12 2011-02-11 Liposome system for ocular administration WO2011098578A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30375810P 2010-02-12 2010-02-12
DKPA201070051 2010-02-12
US61/303,758 2010-02-12
DKPA201070051 2010-02-12

Publications (2)

Publication Number Publication Date
WO2011098578A2 WO2011098578A2 (en) 2011-08-18
WO2011098578A3 true WO2011098578A3 (en) 2011-10-20

Family

ID=44280689

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/052061 WO2011098578A2 (en) 2010-02-12 2011-02-11 Liposome system for ocular administration

Country Status (1)

Country Link
WO (1) WO2011098578A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2123258A1 (en) 2008-05-23 2009-11-25 Liplasome Pharma A/S Liposomes for drug delivery
DK177532B1 (en) 2009-09-17 2013-09-08 Bio Bedst Aps Medical use of sPLA2 hydrolysable liposomes
US10272040B2 (en) 2010-08-12 2019-04-30 Nanyang Technological University Liposomal formulation for ocular drug delivery
EP2638896A1 (en) * 2012-03-14 2013-09-18 Bioneer A/S Cationic liposomal drug delivery system for specific targeting of human cd14+ monocytes in whole blood
US9630909B2 (en) 2013-06-27 2017-04-25 Mylan Laboratories Ltd Process for the preparation of nepafenac
US9956195B2 (en) * 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery
WO2016172712A2 (en) 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
US11382909B2 (en) 2014-09-05 2022-07-12 Sydnexis, Inc. Ophthalmic composition
US20170246175A1 (en) * 2014-09-24 2017-08-31 Nanyang Technological University Sustained timolol maleate delivery from liposomes for glaucoma therapy and occular hypertension
DK3198035T3 (en) 2014-09-26 2023-01-30 Allarity Therapeutics Europe ApS Methods for predicting drug response
GB201505527D0 (en) 2015-03-31 2015-05-13 Jmedtech Pte Ltd Composition
JP2018521000A (en) 2015-05-29 2018-08-02 シドネキシス，インク． Pharmaceutical formulation stabilized with D2O
WO2017027017A1 (en) * 2015-08-11 2017-02-16 Peregrine Ophthalmic PTE LTD. Stable liposomal formulations of carbonic anhydrase inhibitors for ocular drug delivery
US20170119666A1 (en) * 2015-10-29 2017-05-04 Peregrine Ophthalmic PTE LTD. Stable liposomal formulations of alpha 2 adrenergic agonists for ocular delivery
WO2017184081A1 (en) * 2016-04-19 2017-10-26 Nanyang Technological University Subconjuctival depot forming formulations for ocular drug delivery
US9725769B1 (en) 2016-10-07 2017-08-08 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
AU2017258901A1 (en) 2016-12-30 2018-07-19 Allarity Therapeutics Europe ApS Methods for predicting drug responsiveness in cancer patients
CN110944668A (en) 2017-06-16 2020-03-31 学校法人同志社 Medicament comprising an mTOR inhibitor for treating or preventing ocular symptoms, disorders or diseases and uses thereof
CA3078555A1 (en) 2017-10-06 2019-04-11 Foundry Therapeutics, Inc. Implantable depots for the controlled release of therapeutic agents
CN107982219B (en) * 2017-11-30 2020-09-15 天津中医药大学 Cation-modified pilocarpine hydrochloride flexible nano-liposome ophthalmic preparation and preparation method thereof
CN113244171A (en) * 2021-01-28 2021-08-13 周斌 Timolol maleate liposome gel and preparation method thereof
US20240126101A1 (en) * 2022-09-27 2024-04-18 Coopervision International Limited Sustained fatty acid release from contact lens
US20240118559A1 (en) * 2022-09-27 2024-04-11 Coopervision International Limited Sustained release of oleic acid from contact lenses

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4804539A (en) * 1986-07-28 1989-02-14 Liposome Technology, Inc. Ophthalmic liposomes
US4818537A (en) * 1986-10-21 1989-04-04 Liposome Technology, Inc. Liposome composition for treating dry eye
US5665770A (en) * 1993-11-05 1997-09-09 Gakko Hojin Kinki Daigaku Method for treatment of cataract with radical scavenger
US20040224010A1 (en) * 2002-11-15 2004-11-11 Optime Therapeutics, Inc. Ophthalmic liposome compositions and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0651638B2 (en) 1989-02-13 1994-07-06 新技術事業団 Eye drops for corneal epithelial wound treatment
EP1254143B1 (en) 2000-02-10 2004-09-29 Liplasome Pharma A/S Lipid-based drug delivery systems
CA2647779A1 (en) 2006-03-23 2007-09-27 Liplasome Pharma A/S Lipid based drug delivery systems comprising phospholipase a2 degradable lipids that perform an intramolecular cyclization reaction upon hydrolysis
EP2123258A1 (en) 2008-05-23 2009-11-25 Liplasome Pharma A/S Liposomes for drug delivery

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4804539A (en) * 1986-07-28 1989-02-14 Liposome Technology, Inc. Ophthalmic liposomes
US4818537A (en) * 1986-10-21 1989-04-04 Liposome Technology, Inc. Liposome composition for treating dry eye
US5665770A (en) * 1993-11-05 1997-09-09 Gakko Hojin Kinki Daigaku Method for treatment of cataract with radical scavenger
US20040224010A1 (en) * 2002-11-15 2004-11-11 Optime Therapeutics, Inc. Ophthalmic liposome compositions and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AL-MUHAMMED J ET AL: "IN-VIVO STUDIES ON DEXAMETHASONE SODIUM PHOSPHATE LIPOSOMES", JOURNAL OF MICROENCAPSULATION, vol. 13, no. 3, 1 January 1996 (1996-01-01), TAYLOR AND FRANCIS, BASINGSTOKE, GB, pages 293 - 305, XP009000577, ISSN: 0265-2048 *
LAW S L ET AL: "Acyclovir-containing liposomes for potential ocular delivery - Corneal penetration and absorption", JOURNAL OF CONTROLLED RELEASE, vol. 63, no. 1-2, 1 January 2000 (2000-01-01), ELSEVIER, AMSTERDAM, NL, pages 135 - 140, XP004185078, ISSN: 0168-3659, DOI: 10.1016/S0168-3659(99)00192-3 *
SCHAEFFER H E ET AL: "LIPOSOMES IN TOPICAL DRUG DELIVERY", INVESTIGATIVE OPHTHALMOLOGY AND VISUAL SCIENCE, vol. 22, no. 2, 1982, pages 220 - 227, XP002654442, ISSN: 0146-0404 *

Also Published As

Publication number Publication date
WO2011098578A2 (en) 2011-08-18

Similar Documents

Publication Publication Date Title
WO2011098578A3 (en) Liposome system for ocular administration
WO2012071476A3 (en) Drug eluting ocular implant
WO2010068281A3 (en) Contact lens drug delivery device
WO2012091523A8 (en) Carrier for negatively charged drugs comprising a cationic lipid and a preparation method thereof
WO2014165308A3 (en) Microsphere drug delivery system for sustained intraocular release
WO2015184256A3 (en) Biodegradable lipids for delivery of nucleic acids
WO2008073193A3 (en) Ocular devices and methods of making and using thereof
WO2011091205A3 (en) Intracameral sustained release therapeutic agent implants
PL2262476T3 (en) Drug delivery to the anterior and posterior segments of the eye using eye drops.
MY171920A (en) Prevention and treatment of ocular conditions
WO2013036309A3 (en) Sustained release formulations for delivery of proteins to the eye and methods of preparing same
WO2011053801A3 (en) Methods and cosmetic preparations for the sustained delivery of therapeutic agents to the eye
WO2011106702A3 (en) Sustained delivery of therapeutic agents to an eye compartment
WO2012021107A8 (en) A liposomal formulation for ocular drug delivery
WO2012051575A3 (en) Device for ocular access
WO2012002640A3 (en) Transdermal drug delivery system containing donepezil
WO2010146591A3 (en) Methods and devices for delivery of pharmaceutical agents within orifices of the body
IN2014CN03123A (en)
MX2013000661A (en) Eye drug delivery system.
WO2012066488A3 (en) Bridged spiro[2.4]heptane ester derivatives
WO2012112638A8 (en) Ocular strips
WO2012163827A3 (en) Ophthalmic preparation comprising a pgf2alpha analogue
WO2011159761A3 (en) Punctal plugs with continuous or pulsatile drug release mechanism
WO2011142731A3 (en) Formulations comprising a third generation cephalosporin and clavulanic acid
WO2008027793A3 (en) Ophthalmic pharmaceutical compositions and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11702670

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11702670

Country of ref document: EP

Kind code of ref document: A2